Kinomica company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

kinomica.com

Founded Year

2016

Stage

Growth Equity | Alive

Total Raised

$5.2M

Last Raised

$5.2M | 2 yrs ago

About Kinomica

Kinomica offers KinoScan, a combination of advanced proprietary bioinformatics and LC-MS/MS phosphoproteomics to investigate global cellular signaling activities and reprogramming of biochemical network circuits.

Kinomica Headquarters Location

Alderley Park, Alderly Edge

Macclesfield, England, SK10 4TG,

United Kingdom

+44 (0)7408 813506

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kinomica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kinomica is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Kinomica News

TB Diagnostics company PBD Biotech appoints new CEO

Dec 10, 2021

TB Diagnostics company PBD Biotech appoints new CEO Search jobs Jane Theaker of Kinomica brings expertise in precision medicine and diagnostics PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is appointing Jane Theaker, of precision medicine company Kinomica, as the new CEO and bringing Commercial Director, Jonnie Yewdall, into a full-time role. Worldwide Tuberculosis is only second to COVID-19 as the leading infectious killer, with 1.5 million people dying from TB in 2020. PBD Biotech is developing a diagnostic that identifies TB cells in a sample of blood from humans or other species, allowing early detection of the disease and the opportunity for preventing its transmission. Jane Theaker has a strong track record in precision medicine and novel diagnostics technologies. Her experience includes genomics with AstraZeneca and the co-invention of a new quantitative PCR technology. She headed up a team at Qiagen developing diagnostics kits to FDA standards before joining LGC as VP of R+D within genomics and establishing a precision medicine consultancy DataGC Solutions Ltd.  Tom Green Chairman of PBD Biotech says: “We are delighted that Jane Theaker has agreed to join PBD as our new CEO. Jane comes to us from Kinomica Ltd and brings with her deep experience in diagnostics, leadership, and business development. We are fortunate to have secured Jane’s commitment and enthusiasm for PBD and look forward to working with her.”  Jane comments “I’m absolutely thrilled to be joining PBD Biotech Ltd as CEO. The technology is acknowledged to be a potential game-changer for tuberculosis diagnosis in cattle and humans, allowing the spreaders of the disease to be accurately identified and appropriate action to be taken to protect the un-infected. In 2018 roughly 23% of the world’s population were infected by TB bacteria (CDC figures) so the need for this novel diagnostic technology is immense”  Jane joins at a pivotal stage of PBD Biotech’s growth. Following a successful funding round, the company is pursuing World Organisation for Animal Health (OIE) validation of its diagnostic for Bovine TB. The company also has important early-stage trials underway both in the UK and overseas using Actiphage in a range of human diagnostics applications. Tom explains that 2022 will be an exciting year for PBD as OIE validation of Actiphage will enable commercialisation of the kits and technology in the international bovine marketplace. “Jonnie Yewdall, who has been working on a part-time basis for PBD now becomes full-time and has joined the board as Commercial Director. We all welcome Jonnie to this new role.”  The outgoing CEO Mark Hammond has led the company through this time. Tom says: “We all know how challenging the Covid period has been, we owe Mark a huge debt of gratitude for all the work and achievements of the past 2 years – these include the successful completion of last year’s fundraising and the progress which we have made both in the Bovine and early stages of Human applications for Actiphage. We wish him all the best in his new role.”  Mark Hammond comments: “There is an international, un-met need for a rapid TB diagnostic and it has been rewarding to work with the great team at PBD to move Actiphage closer to this goal. I wish Jane and the team every success in the next exciting stage of its development.” Editor Details

Kinomica Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kinomica Rank

  • When was Kinomica founded?

    Kinomica was founded in 2016.

  • Where is Kinomica's headquarters?

    Kinomica's headquarters is located at Alderley Park, Alderly Edge, Macclesfield.

  • What is Kinomica's latest funding round?

    Kinomica's latest funding round is Growth Equity.

  • How much did Kinomica raise?

    Kinomica raised a total of $5.2M.

  • Who are the investors of Kinomica?

    Investors of Kinomica include BioCity, BGF, Longwall Venture Partners, Alderley Park Ventures and Puffin Point.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.